Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115583 · ClinicalTrials.gov registry record · NA
The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
NCT00115583 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 200 participants.
The verdict
NCT00115583, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the importance of a substance called endothelin. Endothelin is produced by coronary arteries. This study examines this substance to determine whether it has an effect on controlling blood flow in coronary arteries. When these arteries release too much endothelin, the blood flow to the heart muscle is reduced and this may be important in heart conditions. This protocol examines an investigational drug called BQ-123 to see if it blocks the effect of endothelin. We assess the blood flow in the coronaries and evaluate the effects of BQ-123. It is anticipated that this endothelin blocker will open up coronary arteries and increase the blood flow to the heart.
Interventions
- DRUG Drug Infusion (BQ-123)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 1998-11 |
| Est. Completion | 2007-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115583
The ClinicalTrials.gov registry entry for NCT00115583 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drug Infusion (BQ-123) is the first listed.
NCT00115583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00115583 about?
NCT00115583 is a clinical study titled "The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries". The purpose of the study is to assess the importance of a substance called endothelin. Endothelin is produced by coronary arteries. This study examines this substance to determine whether it has an effect on controlling blood flow in coronary arteries. When these arteries release too much endothelin...
What is the current status of trial NCT00115583?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 1998-11. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00115583?
The interventions under investigation include: Drug Infusion (BQ-123) (DRUG).
Who is sponsoring clinical trial NCT00115583?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.